Peripheral blood minimal/measurable residual disease assessed in flow cytometry in acute myeloblastic leukemia

Leukemia. 2019 Jul;33(7):1814-1816. doi: 10.1038/s41375-019-0393-0. Epub 2019 Feb 5.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Flow Cytometry / methods*
  • Humans
  • Leukemia, Myeloid, Acute / drug therapy*
  • Molecular Diagnostic Techniques
  • Neoplasm, Residual / blood*
  • Neoplasm, Residual / diagnosis*
  • Neoplasm, Residual / etiology
  • Prognosis
  • Survival Rate